text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 71-58-9 | Product Number: M1964

Medroxyprogesterone Acetate


Purity: >93.0%(GC)
Synonyms:
  • Medroxyprogesterone 17-Acetate
  • 17α-Acetoxy-6α-methylprogesterone
  • 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-Acetate
Documents:
1G
$38.00
15   ≥20 
5G
$115.00
≥20  ≥20 

* Please contact our distributors or TCI to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.


Product Number M1964
Purity / Analysis Method >93.0%(GC)
Molecular Formula / Molecular Weight C__2__4H__3__4O__4 = 386.53  
Physical State (20 deg.C) Solid
CAS RN 71-58-9
Reaxys Registry Number 2066112
PubChem Substance ID 87560200
MDL Number

MFCD00010483

Specifications
Appearance White to Almost white powder to crystal
Purity(GC) min. 93.0 %
Melting point 203.0 to 209.0 °C
Specific rotation [a]20/D +45.0 to +51.0 deg(C=1, Dioxane)
Properties (reference)
Melting Point 206 °C
Specific Rotation 48° (C=1,Dioxane)
Solubility in water Insoluble
Solubility (very soluble in) Chloroform
Solubility (soluble in) Dimethylformamide
Solubility (slightly sol. in) Alcohol
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H351 : Suspected of causing cancer.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P405 : Store locked up.
Related Laws: / Compliance with laws, Regulations
RTECS# TU5010000
Transport Information:
Application
Medroxyprogesterone acetate: Semi-Synthetic Progestational Agent

Medroxyprogesterone acetate (MPA) and megestrol acetate [M1949], semi-synthetic progestational agents, are effective hormonal treatments for metastatic breast cancer in postmenopausal women. The antineoplastic effect may result from inhibition of pituitary gonadotropin production and resultant decrease in estrogen secretion. In addition, MPA has the pregnancy maintaining effect and the anti-estrogen effect. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Documents
Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents